$1.91
+0.02 (+1.06%)
Open$1.90
Previous Close$1.89
Day High$1.92
Day Low$1.89
52W High$3.06
52W Low$1.80
Volume—
Avg Volume50.3K
Market Cap58.69M
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+526.7% upside
Current
$1.91
$1.91
Target
$11.97
$11.97
$8.96
$11.97 avg
$15.34
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 51.54M | 48.92M | 53.08M |
| Net Income | -6,374,638 | -6,659,114 | -5,888,081 |
| Profit Margin | -12.4% | -13.6% | -11.1% |
| EBITDA | -7,191,271 | -7,364,625 | -7,497,793 |
| Free Cash Flow | -8,326,283 | -5,338,476 | -7,416,749 |
| Rev Growth | +3.4% | -7.2% | +0.9% |
| Debt/Equity | 0.61 | 0.70 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |